{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:50:29Z","timestamp":1793749829223,"version":"4.6.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chinese Society of Cardiology Foundation","award":["CSCF2019A01"],"award-info":[{"award-number":["CSCF2019A01"]}]},{"name":"a research grant from Jiangsu Hengrui Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04374-7","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:02:00Z","timestamp":1759230120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["BMI differences on anticoagulation with bivalirudin vs. heparin during primary PCI: a BRIGHT-4 subanalysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Dali","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaohan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanshan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jidong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiutang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renli","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinpin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiqiu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"25 Pt B","key":"4374_CR1","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","volume":"63","author":"MD Jensen","year":"2014","unstructured":"Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985\u20133023.","journal-title":"J Am Coll Cardiol."},{"issue":"9536","key":"4374_CR2","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/S0140-6736(06)69251-9","volume":"368","author":"A Romero-Corral","year":"2006","unstructured":"Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006;368(9536):666\u201378.","journal-title":"Lancet"},{"issue":"24","key":"4374_CR3","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA\/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139\u2013228.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"4374_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119\u201377.","journal-title":"Eur Heart J"},{"key":"4374_CR5","doi-asserted-by":"publisher","first-page":"i2156","DOI":"10.1136\/bmj.i2156","volume":"353","author":"D Aune","year":"2016","unstructured":"Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S, et al. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ. 2016;353:i2156.","journal-title":"BMJ."},{"issue":"10046","key":"4374_CR6","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0140-6736(16)30175-1","volume":"388","author":"E Di Angelantonio","year":"2016","unstructured":"Global BMIMC, Di Angelantonio E, Bhupathiraju S, Wormser D, Gao P, Kaptoge S, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388(10046):776\u201386.","journal-title":"Lancet."},{"issue":"4","key":"4374_CR7","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0735-1097(01)01802-2","volume":"39","author":"L Gruberg","year":"2002","unstructured":"Gruberg L, Weissman NJ, Waksman R, Fuchs S, Deible R, Pinnow EE, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol. 2002;39(4):578\u201384.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"4374_CR8","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jcin.2017.03.013","volume":"10","author":"EW Holroyd","year":"2017","unstructured":"Holroyd EW, Sirker A, Kwok CS, Kontopantelis E, Ludman PF, De Belder MA, et al. The Relationship of Body Mass Index to Percutaneous Coronary Intervention Outcomes: Does the Obesity Paradox Exist in Contemporary Percutaneous Coronary Intervention Cohorts? Insights From the British Cardiovascular Intervention Society Registry. JACC Cardiovasc Interv. 2017;10(13):1283\u201392.","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"4374_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/eurheartj\/ehs217","volume":"34","author":"O Angeras","year":"2013","unstructured":"Angeras O, Albertsson P, Karason K, Ramunddal T, Matejka G, James S, et al. Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry. Eur Heart J. 2013;34(5):345\u201353.","journal-title":"Eur Heart J"},{"issue":"2","key":"4374_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/eurheartj\/ehp317","volume":"31","author":"CE Hastie","year":"2010","unstructured":"Hastie CE, Padmanabhan S, Slack R, Pell AC, Oldroyd KG, Flapan AD, et al. Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention. Eur Heart J. 2010;31(2):222\u20136.","journal-title":"Eur Heart J"},{"issue":"3","key":"4374_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/17425255.2018.1440287","volume":"14","author":"C Smit","year":"2018","unstructured":"Smit C, De Hoogd S, Bruggemann RJM, Knibbe CAJ. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol. 2018;14(3):275\u201385.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"19","key":"4374_CR12","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.jcin.2022.08.031","volume":"15","author":"JE Cigarroa","year":"2022","unstructured":"Cigarroa JE, Anderson HVS. Antithrombotic therapies and body mass index: does one size fit all? JACC Cardiovasc Interv. 2022;15(19):1961\u20134.","journal-title":"JACC Cardiovasc Interv"},{"issue":"10366","key":"4374_CR13","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","volume":"400","author":"Y Li","year":"2022","unstructured":"Li Y, Liang Z, Qin L, Wang M, Wang X, Zhang H, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. Lancet. 2022;400(10366):1847\u201357.","journal-title":"Lancet"},{"key":"4374_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/CD9.0000000000000068","author":"Z Liang","year":"2022","unstructured":"Liang Z, Li Y, Stone GW, Han Y. Rationale and design of a randomized controlled trial of bivalirudin with a prolonged high-dose infusion versus heparin monotherapy during primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: the BRIGHT-4 trial. Cardiol Discov. 2022. https:\/\/doi.org\/10.1097\/CD9.0000000000000068.","journal-title":"Cardiol Discov"},{"key":"4374_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/CD9.0000000000000016","author":"Y Li","year":"2021","unstructured":"Li Y, Li Y, Stone GW, Han Y. Bivalirudin in primary PCI: can its glory being restored? Cardiol Discov. 2021. https:\/\/doi.org\/10.1097\/CD9.0000000000000016.","journal-title":"Cardiol Discov"},{"key":"4374_CR16","doi-asserted-by":"publisher","first-page":"102039","DOI":"10.1016\/j.eclinm.2023.102039","volume":"63","author":"GF Romiti","year":"2023","unstructured":"Romiti GF, Corica B, Proietti M, Mei DA, Frydenlund J, Bisson A, et al. Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry. EClinicalMedicine. 2023;63:102039.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"4374_CR17","doi-asserted-by":"publisher","first-page":"e023907","DOI":"10.1161\/JAHA.121.023907","volume":"11","author":"V Bayer","year":"2022","unstructured":"Bayer V, Kotalczyk A, Kea B, Teutsch C, Larsen P, Button D, et al. Global oral anticoagulation use varies by region in patients with recent diagnosis of atrial fibrillation: the GLORIA-AF phase III registry. J Am Heart Assoc. 2022;11(6):e023907.","journal-title":"J Am Heart Assoc"},{"key":"4374_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2024-003109","author":"CY Cheng","year":"2025","unstructured":"Cheng CY, Lian TY, Zhu XJ, Virdone S, Sun K, Camm J, et al. Atrial fibrillation outcomes in patients from Asia and non-Asia countries: insights from GARFIELD-AF. Open Heart. 2025. https:\/\/doi.org\/10.1136\/openhrt-2024-003109.","journal-title":"Open Heart"},{"issue":"6","key":"4374_CR19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0002-9149(96)00386-4","volume":"78","author":"SG Ellis","year":"1996","unstructured":"Ellis SG, Elliott J, Horrigan M, Raymond RE, Howell G. Low-normal or excessive body mass index: newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention. Am J Cardiol. 1996;78(6):642\u20136.","journal-title":"Am J Cardiol"},{"issue":"5","key":"4374_CR20","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S0735-1097(02)01687-X","volume":"39","author":"HS Gurm","year":"2002","unstructured":"Gurm HS, Whitlow PL, Kip KE. The impact of body mass index on short- and long-term outcomes inpatients undergoing coronary revascularization. Insights from the bypass angioplasty revascularization investigation (BARI). J Am Coll Cardiol. 2002;39(5):834\u201340.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"4374_CR21","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s00392-020-01604-1","volume":"109","author":"M Ono","year":"2020","unstructured":"Ono M, Chichareon P, Tomaniak M, Kawashima H, Takahashi K, Kogame N, et al. The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS trial. Clin Res Cardiol. 2020;109(9):1125\u201339.","journal-title":"Clin Res Cardiol"},{"issue":"6","key":"4374_CR22","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1161\/CIRCULATIONAHA.121.056076","volume":"145","author":"S Song","year":"2022","unstructured":"Song S, Tien CL, Cui H, Basil P, Zhu N, Gong Y, et al. Myocardial rev-erb-mediated diurnal metabolic rhythm and obesity paradox. Circulation. 2022;145(6):448\u201364.","journal-title":"Circulation"},{"key":"4374_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.trsl.2022.10.004","volume":"254","author":"FG Thankam","year":"2023","unstructured":"Thankam FG, Sedighim S, Kuan R, Agrawal DK. Ischemia challenged epicardial adipose tissue stem cells-derived extracellular vesicles alter the gene expression of cardiac fibroblasts to cardiomyocyte like phenotype. Transl Res. 2023;254:54\u201367.","journal-title":"Transl Res"},{"issue":"13","key":"4374_CR24","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1001\/jama.2015.2323","volume":"313","author":"Y Han","year":"2015","unstructured":"Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA. 2015;313(13):1336\u201346.","journal-title":"JAMA"},{"issue":"21","key":"4374_CR25","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","volume":"358","author":"GW Stone","year":"2008","unstructured":"Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218\u201330.","journal-title":"N Engl J Med"},{"key":"4374_CR26","doi-asserted-by":"crossref","unstructured":"Steg PG, van T HA, Hamm CW, Clemmensen P, Lapostolle F, Coste P, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013;369(23):2207\u201317.","DOI":"10.1056\/NEJMoa1311096"},{"issue":"9957","key":"4374_CR27","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","volume":"384","author":"A Shahzad","year":"2014","unstructured":"Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014;384(9957):1849\u201358.","journal-title":"Lancet"},{"issue":"12","key":"4374_CR28","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","volume":"377","author":"D Erlinge","year":"2017","unstructured":"Erlinge D, Omerovic E, Frobert O, Linder R, Danielewicz M, Hamid M, et al. Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med. 2017;377(12):1132\u201342.","journal-title":"N Engl J Med"},{"issue":"9 Pt 2","key":"4374_CR29","first-page":"3711","volume":"41","author":"MA Kirschner","year":"1981","unstructured":"Kirschner MA, Ertel N, Schneider G. Obesity, hormones, and cancer. Cancer Res. 1981;41(9 Pt 2):3711\u20137.","journal-title":"Cancer Res"},{"key":"4374_CR30","doi-asserted-by":"publisher","first-page":"921504","DOI":"10.3389\/fendo.2022.921504","volume":"13","author":"F Lizcano","year":"2022","unstructured":"Lizcano F. Roles of estrogens, estrogen-like compounds, and endocrine disruptors in adipocytes. Front Endocrinol (Lausanne). 2022;13:921504.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"4374_CR31","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2012-01-405498","volume":"120","author":"MC Valera","year":"2012","unstructured":"Valera MC, Gratacap MP, Gourdy P, Lenfant F, Cabou C, Toutain CE, et al. Chronic estradiol treatment reduces platelet responses and protects mice from thromboembolism through the hematopoietic estrogen receptor alpha. Blood. 2012;120(8):1703\u201312.","journal-title":"Blood"},{"issue":"21","key":"4374_CR32","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/j.jacc.2016.02.073","volume":"67","author":"BS Salter","year":"2016","unstructured":"Salter BS, Weiner MM, Trinh MA, Heller J, Evans AS, Adams DH, et al. Heparin-Induced Thrombocytopenia: A Comprehensive Clinical Review. J Am Coll Cardiol. 2016;67(21):2519\u201332.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"4374_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrcardio.2017.18","volume":"14","author":"F Franchi","year":"2017","unstructured":"Franchi F, Rollini F, Angiolillo DJ. Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol. 2017;14(6):361\u201379.","journal-title":"Nat Rev Cardiol"},{"issue":"9696","key":"4374_CR34","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(09)61484-7","volume":"374","author":"R Mehran","year":"2009","unstructured":"Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374(9696):1149\u201359.","journal-title":"Lancet"},{"issue":"16","key":"4374_CR35","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.2165\/0003495-200868160-00006","volume":"68","author":"ED Deeks","year":"2008","unstructured":"Deeks ED, Curran MP. Bivalirudin: in patients with acute coronary syndromes: planned for urgent or early intervention. Drugs. 2008;68(16):2345\u201356.","journal-title":"Drugs"},{"issue":"20","key":"4374_CR36","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1182\/blood-2013-05-427708","volume":"122","author":"F Samad","year":"2013","unstructured":"Samad F, Ruf W. Inflammation, obesity, and thrombosis. Blood. 2013;122(20):3415\u201322.","journal-title":"Blood"},{"issue":"9","key":"4374_CR37","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/cvr\/cvx086","volume":"113","author":"G Vilahur","year":"2017","unstructured":"Vilahur G, Ben-Aicha S, Badimon L. New insights into the role of adipose tissue in thrombosis. Cardiovasc Res. 2017;113(9):1046\u201354.","journal-title":"Cardiovasc Res"},{"issue":"6","key":"4374_CR38","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.ahj.2010.03.011","volume":"159","author":"C Delhaye","year":"2010","unstructured":"Delhaye C, Wakabayashi K, Maluenda G, Belle L, Ben-Dor I, Gonzalez MA, et al. Body mass index and bleeding complications after percutaneous coronary intervention: does bivalirudin make a difference? Am Heart J. 2010;159(6):1139\u201346.","journal-title":"Am Heart J"},{"issue":"9","key":"4374_CR39","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/cvr\/cvx106","volume":"113","author":"AS Antonopoulos","year":"2017","unstructured":"Antonopoulos AS, Tousoulis D. The molecular mechanisms of obesity paradox. Cardiovasc Res. 2017;113(9):1074\u201386.","journal-title":"Cardiovasc Res"},{"issue":"19","key":"4374_CR40","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.jacc.2010.11.058","volume":"57","author":"T Coutinho","year":"2011","unstructured":"Coutinho T, Goel K, Correa DSD, Kragelund C, Kanaya AM, Zeller M, et al. Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data. J Am Coll Cardiol. 2011;57(19):1877\u201386.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"4374_CR41","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1093\/eurheartj\/ehad083","volume":"44","author":"JH Butt","year":"2023","unstructured":"Butt JH, Petrie MC, Jhund PS, Sattar N, Desai AS, Kober L, et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. Eur Heart J. 2023;44(13):1136\u201353.","journal-title":"Eur Heart J"},{"issue":"7","key":"4374_CR42","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S0002-9149(03)00031-6","volume":"91","author":"CJ Lavie","year":"2003","unstructured":"Lavie CJ, Osman AF, Milani RV, Mehra MR. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol. 2003;91(7):891\u20134.","journal-title":"Am J Cardiol"},{"issue":"24","key":"4374_CR43","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1093\/eurheartj\/ehae236","volume":"45","author":"D-H Lee","year":"2024","unstructured":"Lee D-H. Obesity paradox can be a fact: unveiling the hidden role of adipose tissue. Eur Heart J. 2024;45(24):2167.","journal-title":"Eur Heart J"},{"issue":"10383","key":"4374_CR44","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/S0140-6736(23)00270-2","volume":"401","author":"Y Li","year":"2023","unstructured":"Li Y, Liang Z, Stone GW, Han Y. BRIGHT-4 trial: bivalirudin strikes back - authors\u2019 reply. Lancet. 2023;401(10383):1158.","journal-title":"Lancet"},{"key":"4374_CR45","doi-asserted-by":"publisher","first-page":"117395","DOI":"10.1016\/j.atherosclerosis.2023.117395","volume":"390","author":"D Zhang","year":"2024","unstructured":"Zhang D, Li P, Qiu M, Liang Z, He J, Li Y, et al. Net clinical benefit of clopidogrel versus ticagrelor in elderly patients carrying CYP2C19 loss-of-function variants with acute coronary syndrome after percutaneous coronary intervention. Atherosclerosis. 2024;390:117395.","journal-title":"Atherosclerosis"},{"issue":"1","key":"4374_CR46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10557-021-07201-2","volume":"37","author":"Z Li","year":"2023","unstructured":"Li Z, Yang P, A G, Sun H, Liu H, Song X, et al. Early guideline-directed medical therapy and in-hospital major bleeding risk in ST-elevation myocardial infarction patients treated with percutaneous coronary intervention: findings from the CCC-ACS project. Cardiovasc Drugs Ther. 2023;37(1):117\u201327.","journal-title":"Cardiovasc Drugs Ther"},{"key":"4374_CR47","doi-asserted-by":"publisher","first-page":"769165","DOI":"10.3389\/fcvm.2021.769165","volume":"8","author":"X Wang","year":"2021","unstructured":"Wang X, Zhao G, Zhou M, Ma C, Ge J, Huo Y, et al. Trends in bleeding events among patients with acute coronary syndrome in China, 2015 to 2019: insights from the CCC-ACS project. Front Cardiovasc Med. 2021;8:769165.","journal-title":"Front Cardiovasc Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04374-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04374-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04374-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:14:00Z","timestamp":1759234440000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04374-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4374"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04374-7","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial protocol was approved by the ethics committee of the General Hospital of Northern Theater Command (NO. k-2018-3). The study complied with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants or their legally authorized representatives before randomization.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GWS has received speaker honoraria from Medtronic, Amgen, Boehringer Ingelheim; has served as a consultant to Robocath, Daiichi Sankyo, Vectorious, Miracor, Apollo Therapeutics, Cardiac Success, Occlutech, Millennia Biopharma, Remote Cardiac Enablement, Ablative Solutions, Abbott, Oxitope, Valfix, Zoll, HeartFlow, Shockwave, Impulse Dynamics, Adona Medical, HighLife, Elixir, Elucid Bio, Aria, Alleviant, FBR Medical, Myochron, Colibri; and has equity\/options from Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, Xenter. Dr. Stone\u2019s employer, Mount Sinai Hospital, receives research grants from Shockwave, Biosense-Webster, Bioventrix, Abbott, Abiomed, Cardiovascular Systems Inc, Phillips, Vascular Dynamics, Pulnovo, V-wave and PCORI (via Weill Cornell Medical Center). No other conflicts of interest were declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"525"}}